SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Laboratories declines on reporting consolidated net loss of Rs 185.92 crore in Q1FY15

30 Jul 2014 Evaluate

Ranbaxy Laboratories is currently trading at Rs. 586.95, down by 3.05 points or 0.52% from its previous closing of Rs. 590.00 on the BSE.

The scrip opened at Rs. 588.00 and has touched a high and low of Rs. 596.85 and Rs. 575.65 respectively. So far 178776 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 592.00 on 28-Jul-2014 and a 52 week low of Rs. 253.95 on 02-Aug-2013.

Last one week high and low of the scrip stood at Rs. 596.85 and Rs. 554.40 respectively. The current market cap of the company is Rs. 24900.18 crore.

The promoters holding in the company stood at 63.40% while Institutions and Non-Institutions held 20.53% and 13.65% respectively.

Ranbaxy Laboratories has reported net profit of Rs 755.12 crore for the quarter under review as compared to a net loss of Rs 608.80 crore for the quarter ended June 30, 2013. The company’s total income has increased by 49.96% to Rs 2204.39 crore for the quarter under review from Rs 1469.93 crore for the corresponding quarter of the previous year.

On the consolidated basis, the company has reported a net loss after taxes and Minority Interest and Share of Profit of Associates of Rs 185.92 crore for the quarter as compared to net loss of Rs 524.24 crore for the same quarter in the previous year. Besides, total income of the company has decreased by 8.16% at Rs 2451.70 crore for quarter under review as compared to Rs 2669.58 crore for the quarter ended June 30, 2013.

 

Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×